<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086034</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0221</org_study_id>
    <nct_id>NCT00086034</nct_id>
  </id_info>
  <brief_title>Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to find out if motexafin gadolinium may be an effective&#xD;
      treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side&#xD;
      effects of motexafin gadolinium will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <enrollment>35</enrollment>
  <condition>Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL&#xD;
             (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and&#xD;
             mucosa-associated lymphoid tissue (MALT) types&#xD;
&#xD;
          -  Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a&#xD;
             single agent or in combination with chemotherapy&#xD;
&#xD;
          -  ECOG performance status score either 0 or 1&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Laboratory values of:&#xD;
&#xD;
          -  Platelet count &lt; 50,000/µL&#xD;
&#xD;
          -  AST or ALT &gt; 2 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x ULN&#xD;
&#xD;
          -  Creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
        and&#xD;
&#xD;
          -  Greater than three prior regimens (where a regimen is defined as a treatment for NHL&#xD;
             given after disease progression)&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Known history of porphyria, G6PD deficiency, HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brad Kahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>June 21, 2004</study_first_submitted>
  <study_first_submitted_qc>June 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2004</study_first_posted>
  <last_update_submitted>May 11, 2007</last_update_submitted>
  <last_update_submitted_qc>May 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2007</last_update_posted>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Indolent lymphoma</keyword>
  <keyword>Relapsed lymphoma</keyword>
  <keyword>Refractory lymphoma</keyword>
  <keyword>Motexafin gadolinium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

